The Neutralizing Antibody Scientific Research Support Component will provide essential laboratory and scientific support for CHAVI- by performing high throughput assessments of neutralizing activity against tier 1 and tier 2 reference HlV-1 strains in standardized and validated assays. In addition, we will map the epitopes of broadly neutralizing sera and mAbs, monitor vaccine-elicited nAb responses to identify improved immunogens, adjuvants and vectors, and delineate nAbs as a correlate of protection using breakthrough viruses from phase 2b trials.
Specific Aims Aim 1. To support CHAVI-ID research by defining the magnitude and breadth (M-B) of neutralizing activity in sera from select clinical groups, and by mapping the epitopes of broadly neutralizing sera.
Aim 2. To support CHAVI-ID research by screening memory B cell culture supernatants to identify nAb-producing B cells.
Aim 3. To support CHAVI-ID research by characterizing new mAbs for magnitude and breadth of neutralizing activity and epitope specificity.
Aim 4. To support CHAVI-ID research by monitoring the magnitude and breadth of vaccine-elicited nAbs in animals, human vaccinees, and by assessing vaccine sera neutralization with viruses from vaccine breakthrough infections in humans.
Immunogens that elicit broadly cross-reactive neutralizing antibodies may be important for effective vaccination against HlV-1. Vaccines are the most effective and affordable intervention to control the spread of infectious diseases such as AIDS.
|Pollara, Justin; Easterhoff, David; Fouda, Genevieve G (2017) Lessons learned from human HIV vaccine trials. Curr Opin HIV AIDS 12:216-221|
|Arakelyan, Anush; Fitzgerald, Wendy; King, Deborah F et al. (2017) Flow virometry analysis of envelope glycoprotein conformations on individual HIV virions. Sci Rep 7:948|
|Go, Eden P; Ding, Haitao; Zhang, Shijian et al. (2017) Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. J Virol 91:|
|Verkoczy, Laurent; Alt, Frederick W; Tian, Ming (2017) Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies. Immunol Rev 275:89-107|
|Haynes, Barton F; Mascola, John R (2017) The quest for an antibody-based HIV vaccine. Immunol Rev 275:5-10|
|Bonsignori, Mattia; Liao, Hua-Xin; Gao, Feng et al. (2017) Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. Immunol Rev 275:145-160|
|Kelsoe, Garnett; Haynes, Barton F (2017) What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling. Cold Spring Harb Perspect Biol :|
|Herschhorn, Alon; Sodroski, Joseph (2017) An entry-competent intermediate state of the HIV-1 envelope glycoproteins. Receptors Clin Investig 4:|
|Ding, Shilei; Verly, Myriam M; Princiotto, Amy et al. (2017) Short Communication: Small-Molecule CD4 Mimetics Sensitize HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity by Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Nonhuman Primates. AIDS Res Hum Retroviruses 33:428-431|
|Espy, Nicole; Pacheco, Beatriz; Sodroski, Joseph (2017) Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor. Virology 508:90-107|
Showing the most recent 10 out of 220 publications